Digital twin technology integrated with AI is revolutionizing pharmaceutical manufacturing by enhancing efficiency and reliability. Collaborative efforts between CARES and A*STAR I2R have led to the development of a sophisticated system where the digital twin’s ontology and physical modeling are combined with an AI agent for anomaly detection. By merging physical and data-driven models, this AI agent can proactively identify issues like flow rate discrepancies and abnormal tank levels, preventing potential escalations in real-time manufacturing processes.
The system’s capabilities were showcased using a live manufacturing testbed provided by Accelerated Materials, a spin-off of CARES, and hosted on the Microsoft Azure cloud platform. This setup allows researchers and engineers to monitor plant performance in real-time, simulate various production scenarios, and test responses to potential faults, thereby optimizing operational efficiency and reliability.
Key figures involved in the project, such as Prof. Alexei Lapkin and Dr. Lianlian Jiang, emphasize the transformative potential of this technology. Prof. Lapkin highlights the development of technology for rapid digital twin creation based on first principles models, with plans for commercialization through another CARES spin-off, Chemical Data Intelligence. Dr. Jiang discusses how the AI agent within the digital twin can extend beyond anomaly detection to areas like quality monitoring, production scheduling, and resource planning, thereby enhancing overall manufacturing processes.
The project, “From Digital Twins to Real Time AI-Supported Plant Operations,” receives support from ASTAR under the Pharma Innovation Programme Singapore (PIPS), underscoring the commitment to advancing technological solutions in the pharmaceutical sector. ASTAR, Singapore’s primary public sector R&D agency, plays a pivotal role in fostering innovation and collaboration within the industry to drive sustainable growth and development.
CARES, established as the University of Cambridge’s first overseas research center, collaborates with various academic institutions and industrial partners globally to drive advancements in research and technology. With funding from the National Research Foundation (NRF), CARES spearheads decarbonization programs in chemical technologies and manufacturing processes, contributing to the evolution of sustainable practices within the pharmaceutical and related industries.
The integration of digital twin technology with AI not only enhances anomaly detection in pharmaceutical manufacturing but also offers a range of strategic and practical advantages for industry stakeholders. By embedding domain knowledge into the system, crucial expertise can be captured and transferred, enabling streamlined operations and improved decision-making processes. The scalability of this technology to accommodate complex manufacturing environments underscores its potential to revolutionize the industry landscape.
- The collaboration between CARES and A*STAR I2R showcases the potential of digital twin technology integrated with AI for anomaly detection in pharmaceutical manufacturing.
- The AI agent within the digital twin system extends beyond anomaly detection to support quality monitoring, production scheduling, and resource planning, enhancing overall operational efficiency.
- The project’s alignment with A*STAR’s Pharma Innovation Programme Singapore (PIPS) reflects a strategic commitment to advancing technological solutions in the pharmaceutical sector.
- Digital twin technology integrated with AI not only optimizes manufacturing processes but also facilitates knowledge capture and transfer, enabling enhanced decision-making capabilities.
Tags: pharmaceutical manufacturing, automation, digital twins
Read more on manilatimes.net